Join our daily newsletter At The Bell to receive exclusive market insights
- Digital healthcare platform provider Opyl (OPL) has signed two new contracts which will deliver ongoing revenues and help get the company out of the red
- While specific details of the contracts are yet unknown, the two new deals will return Opyl to a position of cash flow neutral this quarter, or better
- The company’s U.K.-based collaboration with digital life sciences platform provider huumun is already bearing fruit — bringing in one of the new contracts with a multinational pharmaceutical company
- The company is hoping its healthcare-specific focus will uniquely position the company to grow in step with the new needs of medical providers
- Opyl was trading 38.9 per cent higher today before entering a trading halt pending a further announcement. Company shares are currently priced at 10 cents each
Digital healthcare platform provider Opyl (OPL) has signed new contracts which will deliver revenues over the next three quarters and help get the company out of the red.
While the details of the contracts are not yet public knowledge, the company states the two new deals will return Opyl to a position of cash flow neutral this quarter, or better.
Given the new need in the healthcare sector for online platforms, including tools for information, marketing and clinical trial recruitment, Opyl anticipates further contracts in coming months will put the company in a cash flow positive position.
Opyl CEO Michelle Gallaher says the shift to digital platforms in healthcare will be a boon for the company’s bottom line.
“The rapid transition to focus on digital channels and data optimisation in healthcare as a result of COVID-19 is starting to positively impact the business as more and more companies realise the value that Opyl can bring to their programs, technologies and healthcare interests,” she stated.
“Each day we get more companies coming to us to help them with their clinical trial recruitment or market insights.”
Opyl CEO Michelle Gallaher
“We are experiencing our busiest proposal period ever, as remote working and acceleration of social media use in healthcare highlights the benefits and importance of digital and social media outreach,” she added.
The company announced a new UK-based collaboration with digital life sciences platform provider huumun in February, with Opyl hoping this intensive business development campaign will underpin the company’s move into cash flow positive territory in coming months.
One of the two new contracts is with a multinational pharmaceutical company, and has come as a result of the huumun collaboration, with further deals anticipated in the future.
The company is hoping its healthcare-specific focus in social media marketing, management and training, alongside content creation and SEO services, will uniquely position the company to grow in step with the new needs of medical providers.
Opyl was trading 38.9 per cent higher today before entering a trading halt pending a further announcement. Company shares are currently priced at 10 cents each.
